CRISPR Therapeutics AG

CRSP · NASDAQ

A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.

Follow Add to Watchlist Ask Question

NASDAQ CRSP Biotech Gene Editing High Risk Five-Year Double Thesis

Latest ReportMay 8, 2026CRISPR Therapeutics: CASGEVY launch, pipeline proof, and binary riskView report ->Total Reports2Published reportsView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Company filters2 company reports

Add tags

Latest Thesis

CRISPR Therapeutics: CASGEVY launch, pipeline proof, and binary risk

A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.

May 8, 2026Research reportSlides available

Read report Open slides Discussion (0)

CRISPR Therapeutics AGTherapeutics: CASGEVY launch, pipeline proof, and binary riskMay 8, 2026

Member workspace

Financials and workspace tools are for paid members.

Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.

Recent Reports

Compact report index for this company.

View all 2 reports ->